Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;133(3):1969-1974.
doi: 10.1111/jam.15699. Epub 2022 Jul 18.

Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection

Laura Serrano  1   2 , Sonia Algarate  3   4 , Beatriz Herrero-Cortina  2   5   6 , Jessica Bueno  3 , María T González-Barriga  1 , María Ducons  3 , Jesica Montero-Marco  2   5 , Beatriz Acha  1   2 , Ana Taboada  1   2 , Pilar Sanz-Burillo  1   2 , Cristina Yuste  1   2 , Rafael Benito  2   3   4 ; RIPOVAC Study Group
Affiliations

Assessment of humoral immune response to two mRNA SARS-CoV-2 vaccines (Moderna and Pfizer) in healthcare workers fully vaccinated with and without a history of previous infection

Laura Serrano et al. J Appl Microbiol. 2022 Sep.

Abstract

Aims: Presence of anti-S1 region of SARS-CoV-2 spike protein was analysed, at two and eight months, in 477 immunocompetent healthcare workers in Zaragoza, Spain, vaccinated with mRNA-1273 (Moderna) or BNT162b2 (Pfizer).

Methods and results: Antibody analysis was performed with Alinity i System (Abbott). At 2 months, 100% of vaccinated had anti-S1 IgG (mean = 13,285 AU ml-1 ). This value was significantly higher with Moderna (18,192 AU ml-1 ) than with Pfizer (10,441 AU ml-1 ). The mean value of anti-S1 IgG after vaccination was significantly higher in patients with than without previous infection (18,539 vs. 7919 AU ml-1 ); in both groups was significantly higher with Moderna than with Pfizer (21,881 vs. 15,733 AU ml-1 and 11,949 vs. 6387 AU ml-1 ), respectively. At 8 months, 100% of patients were IgG positive, with higher levels with Moderna than with Pfizer. Nevertheless, in ensemble of cases, a mean decrease of antibody levels of 11,025 AU ml-1 was observed.

Conclusion: At 2 and 8 months after vaccination, IgG response persists with both vaccines but with important decrease which suggests the need for revaccination.

Significance and impact of study: The study contributes to know the immune status after vaccination with two of more used anti-SARS-CoV-2 vaccines. This knowledge is important for establishing the best vaccination strategy.

Keywords: Moderna; Pfizer; RIPOVAC; anti-S IgG SARS-CoV-2; healthcare workers; immune response; mRNA SARS-CoV-2 vaccines; post-vaccination.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Baden, L.R. , El Sahly, H.M. , Essink, B. , Kotloff, K. , Frey, S. , Novak, R. et al. (2021) Efficacy and safety of the mRNA‐1273 SARS‐Cov‐2 vaccine. New England Journal of Medicine, 384, 403–416. - PMC - PubMed
    1. Bryan, A. , Pepper, G. , Wener, M.H. , Fink, S.L. , Morishima, C. , Chaudhary, A. et al. (2020) Performance characteristics of the Abbott architect SARS‐CoV‐2 IgG assay and seroprevalence in Boise, Idaho. Journal of Clinical Microbiology, 58, e00941–e00920. - PMC - PubMed
    1. Corman, V.M. , Albarrak, A.M. , Omrani, A.S. , Albarrak, M.A. , Farah, M.E. , Almasri, M. et al. (2016). Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clinical Infectious Diseases, 62, 477–483. - PMC - PubMed
    1. Fuentes, A. , Serrano‐Conde, E. , Roldán, C. , Benito‐Ruesca, R. , Mejías, G. , Sampedro, A. et al. (2021) Antibody response in patients admitted to the hospital with suspected SARS‐CoV‐2 infection: results from a multicenter study across Spain. European Journal of Clinical Microbiology and Infectious Diseases, 29, 1–7. - PMC - PubMed
    1. Jangra, S. , Ye, C. , Rathnasinghe, R. , Stadlbauer, D. , Krammer, F. , Simon, V. et al. (2021) SARS‐CoV‐2 spike E484K mutation reduces antibody neutralisation. Lancet Microbe, 2, e283–e284. - PMC - PubMed